For the last two years Dr.
College of Pharmacy
The study will determine which heart-failure patients are more susceptible to pulmonary edema, a leading cause of death.
Eric Snyder, assistant professor in the University of Arizona College of Pharmacy, is the lead investigator on a $2.2 million, five-year study to determine which heart-failure patients will be more susceptible to the development of pulmonary edema, the abnormal build-up of fluid in the lungs.
Pulmonary edema is a leading cause of hospitalization and death in patients with heart failure.
Awarded by the National Institutes of Health, the grant, "Gene-by-Gene Interactions and Lung Fluid Balance in Patients with Heart Failure," also will allow the research team to seek new therapies that can improve the clearance of fluid from the lungs in patients with heart failure.
Collaborators with Snyder on the grant are Paul Nolan of the UA College of Pharmacy; Dr. Mark Friedman in cardiology at the UA College of Medicine; Dr. Dorothy Gilbertson-Dahdal in radiology at the UA College of Medicine; and Dean Billheimer in statistical consulting at the UA BIO5 Institute.
Complications from heart failure, including pulmonary edema, are among the top reasons for hospital admissions in the U.S. for persons over the age of 65. The development of pulmonary edema results from alterations in the normal balance between factors that influence lung fluid accumulation and those that influence lung fluid removal.
Not all patients with heart failure develop pulmonary edema, even if they have similar clinical characteristics and age, which suggests that a person's genes may contribute to the likelihood of developing pulmonary edema.
The research team will study several genes, both alone and together, that are important in lung fluid clearance. In addition, the researchers will investigate how drug therapy affects lung fluid clearance according to these genes.
College of Pharmacy